BZ371A + tadalafil

**BZ371A + tadalafil** is an investigational, combination therapy for the treatment of erectile dysfunction, especially post-prostatectomy. BZ371A is a spider venom-derived peptide developed by Biozeus Biopharmaceutical S.A., supplied as a topical gel acting at the site of application. Tadalafil is a well-established oral phosphodiesterase 5 inhibitor (PDE5i), marketed globally for erectile dysfunction and benign prostatic hyperplasia. The combination leverages BZ371A's ability to restore local blood flow regulation via a novel mechanism (distinct from NO release modulation targeted by tadalafil) and tadalafil’s PDE5 inhibition, providing synergistic effects for erectile function recovery[1][2][5][7][8]. Phase II results indicate significantly superior efficacy of the combination over tadalafil alone in recovery of erectile function after radical prostatectomy, with a 38% success rate at 30 and 60 days, versus 4-13% for tadalafil monotherapy[1][7].